TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 1
Cytokine Pathways and Their Impact on Plaque Psoriasis
Published on:
Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.
Panelists discuss the questions below in this video.
Cytokines, such as IL-12, IL-23, and type I interferons drive psoriasis through TYK2-dependent Th1 and Th17 signaling. How do these pathways promote inflammation and keratinocyte proliferation? Which pathway do you believe is most critical to suppress for psoriasis control?
